Baseline and change scores for the patients, stratified according to treatment.
| Scores | Sensitivity to Change | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change | Effect Size | SDC | |||||||
| Scoring method (score range) | ADA, n = 24 | Placebo, n = 27 | p | ADA, n = 24 | Placebo, n = 27 | p | ADA, n = 24 | Placebo, n = 27 | ADA, n = 24 | Placebo, n = 27 |
| Berlin | ||||||||||
| Semicoronal (0–24) | 2.0 (3.9) | 4.4 (6.4) | 0.11 | −1.6 (3.4) | −1.1 (2.1) | 0.53 | −0.42 | −0.18 | 1.2 | 1.6 |
| Semiaxial (0–24) | 2.3 (4.0) | 4.0 (5.8) | 0.24 | −1.5 (2.5) | −0.9 (2.1) | 0.37 | −0.36 | −0.15 | 2.0 | 3.1 |
| SPARCC | ||||||||||
| Semicoronal (0–72) | 4.8 (10.4) | 10.1 (14.7) | 0.15 | −4.1 (9.3) | −2.1 (4.7) | 0.33 | −0.40 | −0.14 | 2.4 | 3.8 |
| Semiaxial (0–92) | 5.5 (11.7) | 9.0 (12.8) | 0.32 | −3.8 (8.2) | −2.2 (5.3) | 0.34 | −0.33 | −0.17 | 2.1 | 6.3 |
| Global | ||||||||||
| Semicoronal (0–8) | 1.2 (1.9) | 2.4 (2.7) | 0.06 | −0.8 (1.5) | −0.5 (0.9) | 0.31 | −0.43 | −0.17 | 0.5 | 1.1 |
| Semiaxial (0–8) | 1.3 (1.8) | 2.3 (2.5) | 0.11 | −0.8 (1.2) | −0.4 (0.9) | 0.19 | −0.42 | −0.14 | 0.9 | 1.9 |
The magnetic resonance imaging scores are provided as a mean (SD) of 2 readers. Independent t test was used for comparison of baseline and change values between treatment groups. ADA: adalimumab; SDC: smallest detectable change; SPARCC: Spondyloarthritis Research Consortium of Canada.